Avitia, a Canadian AI cancer testing company, has secured $5M in seed funding from PacBridge Capital Partners to expand its market reach and enhance its technology.
Target Information
Avitia is a Canadian company specializing in AI-powered cancer testing solutions. Under the leadership of CEO James Lumsdaine, the company develops innovative molecular testing technologies aimed at enabling laboratories to quickly identify cancer mutations and determine appropriate treatments.
Avitia’s core offering leverages artificial intelligence to streamline the testing process, allowing cancer centers to perform liquid biopsy assays directly on-site. This capability not only reduces testing duration and overall costs but also enhances patient outcomes by facilitating timely treatment decisions.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology industry in Canada is experiencing significant growth, driven by constant advancements in technology and rising investments in healthcare
Similar Deals
Sectoral Asset Management, Genesys Capital, Desjardins Capital, Seido Capital, Private Investors → Antegrade Medical Inc.
2025
PacBridge Capital Partners
invested in
Avitia
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $5M